The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Mon., May. 29, 1:17 PM

Slide #11. Corium International, Inc. Secondary Offering

Company: Corium International, Inc. (NASDAQ:CORI)
Date announced: 5/24/2017
Shares Offered: 5,600,000
Date of Pricing: 5/25/2017
Price Per Share: $6.25
Secondary Offering Details: Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, announced today that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares will be offered and sold by Corium. Corium also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. -updated 5/25- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the pricing of its underwritten public offering of 5,600,000 shares of common stock at a public offering price of $6.25 per share, with expected gross proceeds to Corium of $35 million. In addition, Corium has granted the underwriters a 30-day option to purchase up to an additional 840,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares will be offered and sold by Corium. The offering is expected to close on May 31, 2017, subject to customary closing conditions.

Corium International is a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products in transdermal and transmucosal delivery systems. Co. has several proprietary programs focusing primarily on the treatment of neurological disorders, with two lead programs in Alzheimer's disease. Co. has developed and is the manufacturer of seven prescription drug and consumer products for its marketing partners. Co. has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins.
Open the CORI Page at The Online Investor »

Company Name:  Corium International Inc
Website:  www.coriumgroup.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding CORI:  2
Total Market Value Held by ETFs:  $310970
Total Market Capitalization:  $208.00M
% of Market Cap. Held by ETFs:  0.15%
 

Open the CORI Page at The Online Investor (in a new window) »

May 29, 2017    1:17 PM Eastern
Quotes delayed 20 minutes



Strong Buy (3.60 out of 4)
75th percentile
(ranked higher than approx. 75% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2017, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.